Alicia Bigica

Satralizumab represents only the second targeted treatment for NMOSD and the first cleared for at-home administration.

The approval is based on findings from a phase 2 clinical trial.

Investigators found a 22% reduction in clinical decline at the 78-week cutoff in the intent to treat population in EMERGE who received high-dose aducanumab, with a similar reduction seen in the opportunity to complete population.